• If you are wondering whether Medtronic's current share price reflects fair value or leaves some room on the table, this article will walk through the key facts you need to weigh.
• Medtronic's stock recently closed at US$100.69, with returns of 2.1% over 7 days, 4.3% over 30 days, 4.8% year to date, 12.9% over 1 year, 32.7% over 3 years and 2.6% over 5 years. This gives helpful context before comparing the price to fundamental value.
• Recent attention on Medtronic has centered around its position as a major medical technology company and ongoing product and portfolio updates, which continue to shape how investors think about its long term prospects. These developments help frame whether the recent share price performance lines up with the underlying business profile or reflects shifting expectations.
• On our valuation checks Medtronic scores 4 out of 6 for being undervalued. This sets up a closer look at how different valuation methods assess the stock and hints at an even broader way to think about value that we will come back to at the end of the article.

Approach 1: Medtronic Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes the cash Medtronic is expected to generate in the future, then discounts those cash flows back to today to estimate what the business might be worth right now.

For Medtronic, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections. The latest twelve month free cash flow is about $5.33b. Analysts provide explicit forecasts for the next few years, and Simply Wall St extrapolates those out further, with projected free cash flow of about $9.94b in 2035. Each of these future cash flows is discounted back to today to reflect the time value of money and risk.

Putting all of this together, the DCF model points to an estimated intrinsic value of about $102.82 per share, compared with the recent share price of $100.69. That implies the stock is around 2.1% undervalued, which is a small gap and suggests the market price is close to the modelled value.

Result: ABOUT RIGHT

Medtronic is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Medtronic Price vs Earnings

For profitable companies like Medtronic, the P/E ratio is a useful shorthand because it links what you pay directly to the earnings the business is already generating. It helps you see how many dollars investors are currently willing to pay for each dollar of earnings.

What counts as a “normal” P/E depends on how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can support a higher P/E. Lower growth or higher risk usually means a lower multiple is seen as reasonable.

Medtronic currently trades on a P/E of 27.10x. That sits below the Medical Equipment industry average of about 31.67x and well below the peer average of roughly 47.46x. Simply Wall St’s Fair Ratio for Medtronic is 35.00x, which is its proprietary view of what the P/E “should” be given factors such as earnings growth, industry, profit margins, market cap and company specific risks.

This Fair Ratio can be more tailored than a simple peer or industry comparison because it adjusts for those fundamentals rather than assuming one size fits all. With Medtronic’s current P/E of 27.10x sitting below the Fair Ratio of 35.00x, this framework points to the shares looking undervalued on earnings.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1422 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Medtronic Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about Medtronic, linked directly to your assumptions for its future revenue, earnings, margins and the fair value you think those numbers support.

On Simply Wall St, Narratives sit on the Community page and let you turn that story into a clear forecast, then into a fair value that you can compare with today’s share price to help decide whether Medtronic looks attractive, fairly priced or expensive to you personally.

Because Narratives update when new information like earnings releases or news is added to the platform, your view of fair value can adjust automatically as the facts change rather than staying frozen in time.

For example, one Medtronic Narrative on the Community page might assume a relatively high fair value based on stronger long term growth and margins, while another might set a lower fair value using more conservative forecasts and a higher discount rate, showing how two investors can look at the same company and reach very different conclusions.

Do you think there's more to the story for Medtronic? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.